

## A NEW APPROACH TO JOYFULLY EMBRACE YOURSELF

Klein, Marco Jan<sup>1</sup>; Ferreira Melo, Elaine<sup>1</sup>; Carulla, Patricia<sup>1</sup>; Grau-Campistany, Ariadna<sup>1</sup>; Pastor, Silvia<sup>1</sup>  
<sup>1</sup>Lipotrue, Carrer Imaginació 12, Pol. Ind. Les Marines, Barcelona (Gavà)

ADIPOGENESIS/LIPOGENESIS

### ADIPOGENESIS/LIPOGENESIS

**qPCR**

**Adipogenesis modulation (fold change vs basal)**

Early differentiation markers: PPAR $\alpha$ , CEBP $\alpha$ , SREBF1, SREBF2, SREBF3, SREBF4, SREBF5, SREBF6, SREBF7, SREBF8, SREBF9, SREBF10, SREBF11, SREBF12, SREBF13, SREBF14, SREBF15, SREBF16, SREBF17, SREBF18, SREBF19, SREBF20, SREBF21, SREBF22, SREBF23, SREBF24, SREBF25, SREBF26, SREBF27, SREBF28, SREBF29, SREBF30, SREBF31, SREBF32, SREBF33, SREBF34, SREBF35, SREBF36, SREBF37, SREBF38, SREBF39, SREBF40, SREBF41, SREBF42, SREBF43, SREBF44, SREBF45, SREBF46, SREBF47, SREBF48, SREBF49, SREBF50, SREBF51, SREBF52, SREBF53, SREBF54, SREBF55, SREBF56, SREBF57, SREBF58, SREBF59, SREBF60, SREBF61, SREBF62, SREBF63, SREBF64, SREBF65, SREBF66, SREBF67, SREBF68, SREBF69, SREBF70, SREBF71, SREBF72, SREBF73, SREBF74, SREBF75, SREBF76, SREBF77, SREBF78, SREBF79, SREBF80, SREBF81, SREBF82, SREBF83, SREBF84, SREBF85, SREBF86, SREBF87, SREBF88, SREBF89, SREBF90, SREBF91, SREBF92, SREBF93, SREBF94, SREBF95, SREBF96, SREBF97, SREBF98, SREBF99, SREBF100.

During adipogenesis: PPAR $\alpha$ , CEBP $\alpha$ , SREBF1, SREBF2, SREBF3, SREBF4, SREBF5, SREBF6, SREBF7, SREBF8, SREBF9, SREBF10, SREBF11, SREBF12, SREBF13, SREBF14, SREBF15, SREBF16, SREBF17, SREBF18, SREBF19, SREBF20, SREBF21, SREBF22, SREBF23, SREBF24, SREBF25, SREBF26, SREBF27, SREBF28, SREBF29, SREBF30, SREBF31, SREBF32, SREBF33, SREBF34, SREBF35, SREBF36, SREBF37, SREBF38, SREBF39, SREBF40, SREBF41, SREBF42, SREBF43, SREBF44, SREBF45, SREBF46, SREBF47, SREBF48, SREBF49, SREBF50, SREBF51, SREBF52, SREBF53, SREBF54, SREBF55, SREBF56, SREBF57, SREBF58, SREBF59, SREBF60, SREBF61, SREBF62, SREBF63, SREBF64, SREBF65, SREBF66, SREBF67, SREBF68, SREBF69, SREBF70, SREBF71, SREBF72, SREBF73, SREBF74, SREBF75, SREBF76, SREBF77, SREBF78, SREBF79, SREBF80, SREBF81, SREBF82, SREBF83, SREBF84, SREBF85, SREBF86, SREBF87, SREBF88, SREBF89, SREBF90, SREBF91, SREBF92, SREBF93, SREBF94, SREBF95, SREBF96, SREBF97, SREBF98, SREBF99, SREBF100.

**Figure 1:** Lipogenesis- and adipogenesis-related gene expression during early and late terminal differentiation (Human preadipocytes; 48 h and 7+2 d treatment with 0.2 mg/mL active ingredient; qPCR, Fig.1)

Positive effects on lipogenesis, lipolysis and adipogenesis indicated by modulation of relevant genes (e.g., upregulation of genes: SLC27A1 1.68-fold, PPAR $\alpha$  1.2-fold, CEBPA 2.21-fold, SREBF1 1.36-fold, FABP4 1.58-fold, SCD 1.82-fold, PPARG 1.98-fold, FASN 2.66-fold and LPL 2.69-fold, and downregulation of genes: LIPE -1.8-fold, ECH1 -1.17-fold and GDF15 -1.70-fold).

**in vitro**

**Lipid content (%)**

Condition	Lipid content (%)
Undifferentiated adipocytes	100%
Differentiated adipocytes	170%
0.1 mg/mL active ingredient	104%
0.15 mg/mL active ingredient	107%
0.2 mg/mL active ingredient	117%

**Figure 2:** Improvement of lipid content (Human preadipocytes; 7+2 d with 0.1, 0.15 and 0.2 mg/mL active ingredient; AdipoRed<sup>TM</sup>, fluorescence  $\lambda=520$  nm, Fig.2)

Positive effects on differentiation, but also on accumulation of lipid content (lipid content by 17%, Fig.2, and perilipin by 33%, Fig.3) in adipocytes, that is essential for a macroscopic plumping effect.

**in vitro**

**Perilipin lipid droplets levels (%)**

Condition	Perilipin lipid droplets levels (%)
Basal	100%
0.3 mg/mL active ingredient	133%

**Figure 3:** Increase of perilipin lipid droplets (Human adipocytes (hAD, 7d); 48 h; 0.3 mg/mL active ingredient; Immunofluorescence (Alexa 488), Fig.3)

**in vitro**

**3% active ingredient (perilipin-1 in green)**

**Figure 4:** Increase of Collagen I (Human Dermal Fibroblast adult (HDFa) treated with supernatant co-culture (HDFa + hAD); 4 d; Immunofluorescence (Alexa 488), Fig.4)

A novelty of the active ingredient's action is the improvement in communication between the hypodermis, mainly adipocytes, and the dermis/adjacent fibroblasts. We found that adiponectin released mainly by adipocytes after treatment with the active ingredient triggered the production of collagen (collagen I by 43%) in adjacent fibroblasts.

**in vitro**

**co-culture**

**IL-8 levels (%)**

Condition	IL-8 levels (%)
Basal	100%
0.1 mg/mL active ingredient	39%
0.2 mg/mL active ingredient	34%
0.3 mg/mL active ingredient	22%

**Figure 5:** Improvement of anti-inflammatory and pro-inflammatory cytokines (Co-culture: Human Dermal Fibroblast, adult (HDFa) and differentiated adipocytes; 24 h with 0.1, 0.2 and 0.3 mg/mL active ingredient; ELISA, Fig.5)

The active ingredient can improve inflammation in dWAT by lowering pro-inflammatory cytokines (IL-8 by -66%) and increasing anti-inflammatory factors (adiponectin by 22%).

**in vitro**

**qPCR**

**Antioxidant activity (Trolox equivalents,  $\mu$ M)**

Condition	Antioxidant activity ( $\mu$ M)
0.1 mg/mL active ingredient	255
0.2 mg/mL active ingredient	404
0.3 mg/mL active ingredient	489

**Figure 6:** Dermal and adipose tissue protection by antioxidant activity (in tube; 0.1, 0.2 and 0.3 mg/mL active ingredient; Trolox Equivalent Antioxidant Capacity TEAC, Fig.6)

Due to its high antioxidant molecule content, the antioxidant activity of the active ingredient (689  $\mu$ M Trolox equivalents) could be confirmed as expected.

**in vitro**

**dWAT aging protection (fold change vs basal)**

COL1A, COL4A, TIMP, MMP

**Figure 7:** Inflammation- and ECM-related gene expression (Human preadipocytes; 47+2 d treatment with 0.2 mg/mL active ingredient; qPCR, Fig.7)

Positive effects on inflammation- and ECM-related gene expression (e.g., upregulation of genes: COL1A1 1.23-fold, COL4A1 1.47-fold, TIMP2 1.42-fold, and downregulation of genes: IL6 -1.56-fold, MMP1 -8.68-fold, MMP3 -2.57-fold and TNFa -1.19-fold)

### ORIGIN

The active ingredient is a unique blend of *Vitis vinifera* and Black Cohosh extracts, and possesses the ability to counteract previously mentioned signs of aging.

*Vitis vinifera* is the Latin name of the common grape vine (Monastrell grape variety from Spain), and its extract is known for the abundance of polyphenols, anthocyanins a subtype of flavonoids, and other antioxidants, which can even be enriched due to the origin of the extract, a so-called callus culture.

The root extract of Black Cohosh, which originally could be found in North America, is very rich in polyphenols and isoflavones.

**in vivo**

**20** Caucasian women  
**50-60** years old (menopausal range)  
**2x** a day, split face  
 timepoints: 7, 14 & 28 days

**Figure 8:** Crow's feet wrinkle volume (28 d treatment with a formulation containing 3% of active ingredient; PRIMOS 3D; Fig.8)

Timepoint	Placebo	Formulation containing 0.3 mg/mL active ingredient
7 days	3.4%	-3.7%
14 days	1.8%	-9.5%
28 days	-0.3%	-10.7%

**Figure 9:** Crow's feet wrinkle volume (28 d treatment with a formulation containing 3% of active ingredient; Visia<sup>®</sup>-CR & PRIMOS 3D images; Fig.9)

**Figure 10:** Nasolabial fold volume (28 d treatment with a formulation containing 3% of active ingredient; PRIMOS 3D; Fig.10)

Timepoint	Placebo	Formulation containing 0.3 mg/mL active ingredient
7 days	0.8%	-1.4%
14 days	2.8%	-4.4%
28 days	6.7%	-8.3%

**Figure 11:** Plumping effect on cheekbones (28 d treatment with a formulation containing 3% of active ingredient; PRIMOS 3D; Fig.11)

Timepoint	Placebo	Formulation containing 0.3 mg/mL active ingredient
7 days	0.04 mm	0.13 mm
14 days	-0.04 mm	0.38 mm
28 days	0.07 mm	0.52 mm

**Figure 12:** Nasolabial fold volume (28 d treatment with a formulation containing 3% of active ingredient; PRIMOS 3D images; Fig.12)

**in vivo**

**10** Caucasian women  
**50-60** years old (menopausal range)  
**2x** a day, whole face  
 timepoint: 28 days

**Figure 13:** Vocal markers of emotional stress (28 d treatment with a formulation containing 3% of active ingredient; were loudness (i.e. vocal intensity) represented by the mean amplitude measured in dB and pitch (i.e. tone) represented by the mean fundamental frequency measured in Hz; Fig.13)

Parameter	Change
Loudness (i.e. vocal intensity)	-4.1 dB
Pitch (i.e. tone)	-5.1 Hz

For a normal human being changes of vocal markers of emotional stress are usually only receivable on a subconscious level, but experts can interpret the change in loudness and pitch, and assign them to an emotional stress level. Loudness could be reduced by -4.1 dB and the vocal pitch could be lowered by -5.1 Hz.

**in vivo**

**MOOD improvement in 28 days (%)**

Mood	Improvement (%)
RELAX (Positive passive Serenity/balance)	7.1%
ACTIVE (Positive active Dynamism)	6.5%
NEGATIVE	-50.0%

**Figure 14:** MOOD improvement in 28 days (28 d treatment with a formulation containing 3% of active ingredient; Projective test: a trio of different images were presented to the volunteers 15 times. They must chose one of the three for each trio at each time. The trio had three emotional dimension; Fig.14)

A projective test revealed that balance (positive passive) could be improved by 7.1%, dynamism (positive active) by 6.5%, and negative emotions could be decreased by 50%. Improvement in skin appearance seems to have a satisfying emotional effect on the consumer, which can be evaluated by the parameters measured.

CLINICAL STUDY-SKIN

CLINICAL STUDY-MOOD

**Conclusion**

The active ingredient induces adipogenesis, lipid accumulation and prevents the adipose tissue aging by modulating its inflammation and increasing the collagen I content in the hypodermis due to the communication between adipocytes and fibroblasts. The active is able to reduce crow's feet and nasolabial wrinkles as a plumper ingredient, soothes erythema and brings radiance to the skin. Also, it increases the positive mood and decreases the vocal markers of stress. These results underline the long-term potential of our product enhancing the mood of people in addition to its general anti-aging benefits.

**References**

- 1) Wollina U, Wetzker R, Abdel-Naser MB, Kruglikov IL. Role of adipose tissue in facial aging. Clin Interv Aging. 2017;12:2069-2076.
- 2) Kruglikov I, Trujillo O, Kristen Q, Isac K, Zorko J, Fam M, Okonkwo K, Mian A, Thanh H, Koban K, Scalfani AP, Steinke H, Cotofana S. The Facial Adipose Tissue: A Revision. Facial Plast Surg. 2016 Dec;32(6):671-682.
- 3) Kruglikov IL, Scherer PE. Skin aging: are adipocytes the next target? Aging (Albany NY). 2016;8(7):1457-1469.
- 4) Ejaz A, Hatzmann FM, Hammerle S, et al. Fibroblast feeder layer supports adipogenic differentiation of human adipose stromal/progenitor cells. Adipocyte. 2019;8(1):178-189.
- 5) Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev. 1998 Jul;78(3):783-809.
- 6) Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007 May 1;380(1-2):24-30.